Literature DB >> 13828827

The status of G-27202 (metabolite 1 of phenylbutazone) in the treatment of rheumatic disorders.

W GRAHAM.   

Abstract

Entities:  

Keywords:  PHENYLBUTAZONE/related compounds; RHEUMATISM/therapy

Mesh：

Substances：

Year:  1960        PMID： 13828827      PMCID： PMC1938363     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN： 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  A controlled trial of phenylbutazone, oxyphenbutazone, and a placebo in the treatment of rheumatoid arthritis.

Authors:  R I MEANOCK; E LEWIS-FANING
Journal:  Ann Rheum Dis       Date:  1961-06       Impact factor: 19.103

2.  Hydroxy-phenylbutazone (Tanderil) in the treatment of ocular disease. A preliminary survey.

Authors:  L E WERNER
Journal:  Br J Ophthalmol       Date:  1960-12       Impact factor: 4.638

3.  Trial of oxyphenbutazone for postoperative edema after bilateral herniorrhaphy.

Authors:  J D ILES
Journal:  Can Med Assoc J       Date:  1963-04-20       Impact factor: 8.262

4.  Effects of oxyphenbutazone (tandearil) on plasma seromucoids. II. In postoperative inflammation.

Authors:  R BARCELO; C LEBLANC; P RIOPEL; L P LEGRESLEY
Journal:  Can Med Assoc J       Date:  1963-03-23       Impact factor: 8.262

5.  Effects of oxyphenbutazone (Tandearil) on plasma seromucoids. I. In experimental inflammation.

Authors:  R BARCELO; P RIOPEL; L P LEGRESLEY
Journal:  Can Med Assoc J       Date:  1963-03-16       Impact factor: 8.262
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.